Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes cardiovascular mortality compared with no intervention (very low certainty).
1 finding from 1 review
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes (a)Non‐fatal myocardial infarction (b)Non‐fatal stroke (c)Congestive… compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
Acarbose probably leads to lower incidence of T2DM compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes cardiovascular mortality compared with placebo (very low certainty).
1 finding from 1 review
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes (a)Non‐fatal myocardial infarction (b)Non‐fatal stroke (c)Congestive… compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Development of type 2 diabetes · people at increased risk for developing type 2 diabetes
It is very uncertain whether acarbose changes incidence of T2DM compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality
Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).
Macrovascular or microvascular complications
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe hypoglycaemia
Adverse events other than severe hypoglycaemic episodes (all non‐severe hypoglycaemic episodes) (Events per participant per month)
1 finding from 1 review
HbA1c (%)
Health‐related quality of life
Socioeconomic effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found